Schizoaffective Disorders Treatment Market

Global Schizoaffective Disorders Treatment Market Size

The global schizoaffective disorders treatment market was worth US$ 7.83 billion in 2025 and is anticipated to reach a valuation of US$ 10.11 billion by 2034 from US$ 8.06 billion in 2026, and it is predicted to register a CAGR of 2.88% during the forecast period 2026 to 2034.

A schizoaffective disorder is a mental health disorder with symptoms such as mania, depression, and schizophrenia tendencies like hallucinations and delusional behavior. Schizoaffective disorder shares symptoms with schizophrenia and bipolar disorder, which can lead to misdiagnosis. According to the Diagnostic and statistical manual of mental Disorders (DMS – 5), 0.3% of the population suffers from a schizoaffective disease where a woman population is more than the men. The typical age for schizoaffective disorder is early adulthood, although it can occur anytime from adolescence through late life.

MARKET DRIVERS

The growing adoption of unenergetic lifestyles and rising incidence of chronic diseases are propelling the global schizoaffective disorders treatment market growth.

People with schizoaffective disorder generally respond to a combination of medications and psychotherapy, and this medicine to the patient depends on the symptoms of the disease. Other methods like psychotherapy, life skills training, hospitalization, and electroconvulsive therapy are for adults who do not respond to psychotherapy or medication. Only one drug that the US FDA approves and many more are in the pipeline stage, propelling the market growth. Ongoing research in the field of schizoaffective disorder is boosting market growth. In addition, the adoption of advanced technology is significantly influencing the market's demand.

The increasing funding toward the schizoaffective drug market is expected to help the revenue along with the growing rates of mental disorders worldwide.

For instance, schizoaffective disorder (1/2%) affects about one in every 200 persons at some point in their lives. One of the most prevalent major mental diseases, along with schizophrenia, is schizoaffective disorder. Furthermore, in the post-COVID era, there has been a rapid increase in mental disorders stats, leading to more revenue for the market. For example, according to WHO, in 2018, 970 million individuals worldwide, or 1 in every eight persons, had a mental illness, including anxiety and depressive disorders. Now, around 19.86% of adults are experiencing a mental illness worldwide. Therefore, there is a need for more awareness and care regarding mental health supporting the market expansion.

MARKET RESTRAINTS

Stringent rules and regulations by the government regarding public safety are slowly declining the market's growth rate. In addition, the diagnosis of schizoaffective disorder is less reliable and is limiting the demand of the market.

REPORT COVERAGE

SEGMENTAL ANALYSIS

By Treatment Insights

The antipsychotic segment is leading with the highest shares of the market. The growth is credited to advanced healthcare facilities and the availability of a well-structured regulatory framework.

The mood stabilizers and antidepressants segment is also expected to dominate the market revenue during the forecast period because common psychological treatments include a combination of these drugs to induce treatment in the patient. Due to multiple symptoms and the need to curb all the problems, these diseases are prescribed to critically ill schizoaffective patients.

By Cause of Disorder Insights

The genetic factors segment is the leading segment of the treatment of schizoaffective disease over the analysis period. Factors like quick improvement in the healthcare industry and the growing healthcare industry propel the market's growth.

The environmental factors segment is also expected to show significant revenue during the forecast period due to the rising levels of stress and pressure among the younger generations and the extensive stereotypes of perfect success in society today.

By Type Insights

The manic segment is considered to hold the largest market share of the schizoaffective disorders treatment market. The growth is due to advance technologies for medical tourism, fast access to the required procedures of the medical field, and lower cost for discretionary processes.

The depressive segment is also expected to show significant growth in the market due to rising cases of youth diagnosed with clinical depression and needing support and help from professionals. The mixed type also prevails as mental disorder diagnoses become more complex and integrated.

REGIONAL ANALYSIS

North America Schizoaffective Disorders Treatment Market Analysis

North America was the largest regional segment for schizoaffective disorders treatment globally in 2024, while Europe and the Asia Pacific regions followed. The dominance of North America and Europe is due to the advanced healthcare infrastructures, strict government rules regarding the production and supply of medications, and the increasing research and development in the field. Additionally, the presence of key market players in countries like the U.S., Canada, the U.K., France, Germany, Italy, etc., is expected to promote market growth in the region.

Asia-Pacific Schizoaffective Disorders Treatment Market Analysis

The Asia-Pacific region is expected to have the fastest growth rate during the forecast period, owing to increasing healthcare spending, rising disposable income, availability of advanced healthcare facilities, and rising awareness about available healthcare facilities. Additionally, the Asia-Pacific market is rising due to the growing preference toward medical tourism and first-class service in countries like China, India, Japan, South Korea, etc., for lower costs than developed regions.

KEY MARKET PLAYERS

Some of the major players in the global schizoaffective disorders treatment market profiled in this report are

• Merz Pharma GmbH & Co. KGaA
• Eli Lilly and Company
• Elan Pharmaceuticals
• Ciba Pharmaceuticals
• Abbott Pharmaceuticals
• AstraZeneca plc
• Janssen-Cilag Pty Limited

GLOBAL SCHIZOAFFECTIVE DISORDERS TREATMENT MARKET NEWS

• In November 2022, Alkermes updated its forecast for its fiscal year 2022 results. In contrast to the average expectation of $0.20, the business announced earnings per share (EPS) guidance of $0.15 to $0.33 for the relevant period. In contrast to the average sales forecast of $1.10 billion, the business provided revenue guidance of $1.07 billion to $1.12 billion.
• In November 2022, Leerink SVB Comments on the earnings for FY2024 of Alkermes plc. In research published on Wednesday, November 2, SVB Leerink lowered their FY2024 earnings per share (EPS) projections for shares of Alkermes. The business will now report earnings of $0.45 per share for the year, down from their previous expectation of $0.57, according to SVB Leerink analyst M. Goodman. The current full-year average estimate for Alkermes' profits is ($0.34) per share.

MARKET SEGMENTATION

This report on the global schizoaffective disorders treatment market report has been segmented and sub-segmented based on treatment, cause of disorder, type, and region.

By Treatment

• Antipsychotics
  • Aripiprazole
  • Clozapine
  • Haloperidol
  • Risperidone
  • Olanzapine
  • Others
• Mood Stabilizers
  • Divalproex
  • Lithium
  • Others
• Antidepressants
  • Desvenlafaxine
  • Fluoxetine
  • Escitalopram
  • Others
• Anticonvulsants
  • Valproate
  • Carbamazepine
  • Others
• Psychotherapy
  • Group Therapy
  • Psychotherapy & Counselling
  • Others

By Cause of Disorder

• Genetic Factors
• Chemical Factors
• Environmental Factors

By Type

• Manic Type
• Depressive Type
• Mixed Type
• Schizoaffective Disorders

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• The Middle East and Africa